Casdin Capital

Investor type Micro VC
Founders Eli Casdin

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 145
Average round size
info
The average size of a deal this fund participated in
$88M
Portfolio companies 119
Rounds per year 16.11
Lead investments 13
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.18
Exits 37
Key employees 2
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Genetics
Summary

Casdin Capital appeared to be the VC, which was created in 2011. The leading representative office of defined VC is situated in the New York. The company was established in North America in United States.

The fund is constantly included in 2-6 investment rounds annually. This Casdin Capital works on 13 percentage points more the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. Considering the real fund results, this VC is 12 percentage points less often commits exit comparing to other organizations. Deals in the range of 50 - 100 millions dollars are the general things for fund. The top amount of exits for fund were in 2018. The typical startup value when the investment from Casdin Capital is more than 1 billion dollars.

The usual cause for the fund is to invest in rounds with 7-8 partakers. Despite the Casdin Capital, startups are often financed by The Column Group, ARCH Venture Partners, Topspin Partners. The meaningful sponsors for the fund in investment in the same round are Foresite Capital, Redmile Group, Wellington Management. In the next rounds fund is usually obtained by Redmile Group, Perceptive Advisors, GV.

We also calculated 2 valuable employees in our database.

The fund has no exact preference in some founders of portfolio startups. When startup sums 1 of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Foundation Medicine, Flatiron Health, 23andMe. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Casdin Capital:
Typical Co-investors
Casdin Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Casdin Capital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Exai Bio

Biotechnology
Health Diagnostics
$67M09 Dec 2021 Palo Alto, California, United States

nplex biosciences

Biotechnology
Health Diagnostics
Market Research
Nanotechnology
$17M08 Dec 2021 Montreal, Quebec, Canada

Lunit

Artificial Intelligence
Computer Vision
Health Diagnostics
Image Recognition
Machine Learning
Medical Device
Software
$61M29 Nov 2021 South Korea, Gyeonggi-do, South Korea

Stilla Technologies

Biotechnology
Genetics
$36M23 Nov 2021 France, Ile-de-France, France

Chroma Medicine

Biotechnology
Medical
Therapeutics
$125M17 Nov 2021 Cambridge, Massachusetts, United States

Beacon Biosignals

Artificial Intelligence
Health Care
Health Diagnostics
Machine Learning
Medical Device
Software
$27M08 Nov 2021 Boston, Massachusetts, United States

Loop Medical

Health Care
Medical Device
Wellness
$6M14 Oct 2021 Lausanne, Vaud, Switzerland

Amplo Biotechnology

Biotechnology
Health Care
Neuroscience
Therapeutics
06 Oct 2021 Pompano Beach, Florida, United States

Exo Therapeutics

Biotechnology
Health Care
Pharmaceutical
$78M05 Oct 2021 Cambridge, Massachusetts, United States
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes

– Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes.
Nextech Invest led the financing, with participation from new investors SoftBank Vision Fund 2* and Casdin Capital, as well as existing investors The Column Group, 8VC, and Two Sigma Ventures.
– Hexagon’s interdisciplinary platform combines technological advances and proprietary insights across machine learning, genomics, synthetic biology and automation to systematically discover new chemical compounds linked to known protein targets.
– Hexagon has built a database of microbial genomes that is more than twice the size of all public databases and is adding thousands of additional genomes per month.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Casdin Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: